AARDVARK THERAPEUTICS, INC. Operating Expenses
AARDVARK THERAPEUTICS, INC. (AARD) reported Operating Expenses of $15.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- AARDVARK THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $15.08M, a 4.82% decline year-over-year.
- AARDVARK THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $22.46M, a 114.56% increase year-over-year.
- AARDVARK THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $18.70M, a 97.93% increase year-over-year.
- AARDVARK THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $17.70M, a 247.73% increase year-over-year.
- AARDVARK THERAPEUTICS, INC. operating expenses for fiscal 2025 was $62.73M, a 175.29% increase from fiscal 2024.
- AARDVARK THERAPEUTICS, INC. operating expenses for fiscal 2024 was $22.79M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.08M 10-Q · filed 2026-08-11 | $37.55M 10-Q · filed 2026-08-11 | $56.25M derived: sum of 3 quarters · filed 2026-08-11 | $73.95M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $22.46M 10-Q · filed 2026-05-07 | $41.17M derived: sum of 2 quarters · filed 2026-05-07 | $58.87M derived: sum of 3 quarters · filed 2026-05-07 | $74.72M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $18.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $36.41M derived: sum of 2 quarters · filed 2026-03-23 | $52.26M derived: sum of 3 quarters · filed 2026-08-11 | $62.73M 10-K · filed 2026-03-23 |
| 2025-09-30 | $17.70M 10-Q · filed 2025-11-13 | $33.55M derived: sum of 2 quarters · filed 2026-08-11 | $44.02M 10-Q · filed 2025-11-13 | $53.47M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $15.85M 10-Q · filed 2026-08-11 | $26.32M 10-Q · filed 2026-08-11 | $35.77M derived: sum of 3 quarters · filed 2026-08-11 | $40.86M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $10.47M 10-Q · filed 2026-05-07 | $19.92M derived: sum of 2 quarters · filed 2026-05-07 | $25.01M derived: sum of 3 quarters · filed 2026-05-07 | $31.08M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $9.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $14.54M derived: sum of 2 quarters · filed 2026-03-23 | $20.61M derived: sum of 3 quarters · filed 2026-03-23 | $22.79M 10-K · filed 2026-03-23 |
| 2024-09-30 | $5.09M 10-Q · filed 2025-11-13 | $11.16M derived: sum of 2 quarters · filed 2025-11-13 | $13.34M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $6.07M 10-Q · filed 2025-08-13 | $8.24M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $2.17M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |